Updated cancer treatment framework offers new guidance on actionability and resistance biomarkers

ESMO has published version 2 of the ESMO Scale for Clinical Actionability of molecular Targets (ESCAT), a major update to the internationally recognized precision oncology framework that helps oncologists assess the clinical relevance of molecular alterations and match patients with the most appropriate targeted therapies.

Read it at Medical Xpress ↗

← Front page